Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials

Key Points

• This research compares the effectiveness and safety of resmetirom and efruxifermin for treating metabolic dysfunction-associated steatohepatitis.
• Conducted a network meta-analysis of randomized controlled trials
• Compared the effects on MRI-PDFF and AST
• Assessed safety outcomes between the two interventions
• Efruxifermin showed a slightly greater effect on MRI-PDFF
• Efruxifermin demonstrated more favorable safety outcomes compared to resmetirom

Abstract